Cencora (COR) Stock Forecast & Price Target

$227.69 +1.42 (+0.63%)

(As of 12/20/2024 05:45 PM ET)

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
2

Buy
9

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for COR.

Consensus Price Target

$275.60
21.04% Upside

According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $275.60. The highest price target for COR is $292.00, while the lowest price target for COR is $237.00. The average price target represents a forecasted upside of 21.04% from the current price of $227.69.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

COR Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$275.60	$271.20	$256.67	$198.67
Forecasted Upside	21.04% Upside	10.47% Upside	12.52% Upside	-2.15% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.04% Upside	25,828.55% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$249.00 ➝ $237.00	+2.07%
12/4/2024	Mizuho 2 of 5 stars	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$280.00	+11.98%
11/7/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$287.00 ➝ $292.00	+17.29%
11/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$275.00 ➝ $285.00	+14.68%
11/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$263.00 ➝ $290.00	+18.18%
11/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$250.00 ➝ $285.00	+16.15%
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
9/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$275.00 ➝ $245.00	+4.46%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$280.00 ➝ $287.00	+20.03%
4/30/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$265.00 ➝ $280.00	+16.87%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$176.00 ➝ $190.00	-1.69%
5/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$174.00 ➝ $182.00	+8.81%
1/12/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$170.00 ➝ $190.00	+14.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:38 AM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

The stock has a current price of $248.47, which reflects a strong market position and investor interest.
Cencora, Inc. has recently increased its quarterly dividend to $0.55, up from $0.51, indicating a commitment to returning value to shareholders.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price of $276.80, suggesting potential for price appreciation.
Ten analysts have assigned a buy rating to the stock, reflecting strong confidence in the company's growth prospects.
The company has a solid market capitalization of approximately $48.96 billion, which provides stability and resources for future growth initiatives.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

The stock has a relatively high price-to-earnings (P/E) ratio of 33.09, which may indicate that it is overvalued compared to its earnings.
Cencora, Inc. has a high debt-to-equity ratio of 4.84, suggesting that the company relies heavily on debt financing, which can be risky in volatile markets.
Insider selling has been significant, with 93,018 shares sold recently, which may raise concerns about the confidence of insiders in the company's future performance.
Recent price fluctuations, including a drop of $3.50 in a single trading session, indicate potential volatility that could deter risk-averse investors.
Two analysts have rated the stock with a hold rating, suggesting that some market participants may not see immediate upside potential.

COR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $275.60, with a high forecast of $292.00 and a low forecast of $237.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 21.04% based on their 12-month stock forecasts.
: Cencora has been rated by research analysts at Barclays, Evercore ISI, Leerink Partners, Mizuho, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Cencora more than other "medical" companies. The consensus rating score for Cencora is 2.82 while the average consensus rating score for "medical" companies is 2.81. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NYSE:COR) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target